Merck's recall of rofecoxib--a strategic perspective.
Oberholzer-Gee
Felix
F
Harvard Business School, Boston, USA.
Inamdar
S Noorein
SN
D003365:Costs and Cost Analysis; D004341:Drug Evaluation / Q000191:economics; D004345:Drug Industry / Q000191:economics* / Q000458:organization & administration* / Q000639:trends; D004335:Drug and Narcotic Control / Q000191:economics*; D006801:Humans; D007783:Lactones / Q000009:adverse effects* / Q000191:economics; D009935:Organizational Affiliation / Q000639:trends; D009936:Organizational Innovation; D012106:Research / Q000191:economics* / Q000639:trends; D013450:Sulfones; D014481:United States
D007783:Lactones; D013450:Sulfones; C116926:rofecoxib